Summary

Nicotine Oral Dissolvable Thin Films Market Research Report Information by Strength (1mg, 2mg, and Others), by Route of Administration (Tongue and Buccal), and by Age Group (Adults and Adolescents), by Sales Channel (Online and Offline), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Overview of the Market
In 2023, the market for nicotine oral dissolvable thin films was estimated to be worth USD 0.10 billion. With a compound annual growth rate (CAGR) of 3.86% from 2024 to 2032, the market for nicotine oral dissolveable thin films is expected to increase from USD 0.11 billion in 2024 to USD 0.15 billion by 2032.
Increased efforts to stop smoking are driving a significant demand for nicotine oral dissolvable thin films, which is accelerating market expansion in a number of ways. Public health campaigns and government initiatives, such those run by the Office on Smoking and Health (OSH), are actively urging people to quit smoking or reduce their nicotine intake. Programs designed to reduce tobacco use support these efforts by providing resources and skills for implementing effective quitting techniques.
Moreover, the worldwide market for nicotine oral dissolvable thin films is mostly driven by the advantages of oral thin film (OTF) technology. A few of the main advantages that support market expansion are listed below. OTFs are a handy and portable way to give nicotine because they dissolve quickly in the mouth and don't require water. They are available for users to use quietly from anywhere at any time.
Perspectives on Market Segments
The market for nicotine oral dissolvable thin films has been divided into segments based on strength, including 1 mg and 2 mg.
The market has been divided into tongue and buccal segments based on the administration route.
The market for nicotine oral dissolvable thin films has been divided into two segments based on age: adults and adolescents.
The market has been divided into online and offline segments based on the sales channel.
Geographic Perspectives

The market for nicotine oral dissolvable thin films in North America was valued at USD 31.20 million in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 3.86% over the course of the forecast period. The United States and Canada are two more divisions of North America. The growing frequency of smoking-related health problems and growing awareness of smoking cessation aids are driving the market for nicotine oral dissolvable thin films in North America.
The market for nicotine oral dissolvable films in Europe was valued at USD 44.48 million in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 3.46% over the course of the forecast period. The market for nicotine oral dissolvable thin films in Europe is expected to increase significantly over the next several years because to the growing demand for these products and the presence of competitors.
The market for nicotine oral dissolvable films in the Asia-Pacific region was valued at USD 20.74 million in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 4.77% over the course of the forecast period. Because of rising health consciousness, urbanization, and the high prevalence of smoking in nations like China, South Korea, India, and Japan, the market for nicotine oral dissolvable thin films in the Asia-Pacific region is expanding significantly.

Key Players
Nicoccino Holding AB (Japan), AdhexPharma (France), ARx, LLC (US), ZIM Laboratories Limited (India), LTS Lohmann Therapie-Systeme AG (Germany), NAL Pharma (China), INVENTZ Lifesciences (India), Renejix Pharma Solutions (US), and DK Livkon Healthcare Pvt. Ltd. (India) are important players in the nicotine oral dissolvable thin film market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY RESEARCH DATA FLOW:
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING SMOKING AND TOBACCO CESSATION EFFORTS
4.2.2 ADVANTAGE OF ORAL THIN FILM DRIVES THE MARKET GROWTH
4.3 RESTRAINTS
4.3.1 STRINGENT REGULATORY POLICIES
4.3.2 PRESENCE OF NICOTINE REPLACEMENT THERAPIES
4.3.3 PATENT PROTECTION OF NICOTINE ORAL THIN FILM PRODUCTS
4.4 OPPORTUNITY
4.4.1 INITIATION TO BUILD AND LAUNCH ORAL THIN FILM MANUFACTURING
4.4.2 INNOVATION ASSOCIATED WITH NICOTINE ORAL THIN FILM
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET
5.4 QUALITATIVE INFORMATION ON PACKAGING OF NICOTINE ORAL DISSOLVABLE THIN FILMS
5.4.1 PACKAGING MATERIALS
5.4.1.1 FOIL, PAPER, OR PLASTIC POUCHES
5.4.1.2 SINGLE POUCH AND ALUMINUM POUCH
5.4.1.3 BLISTER CARD WITH MULTIPLE UNITS
5.4.1.4 BARRIER FILMS
5.4.2 LABELING AND INFORMATION FOR NICOTINE ORAL DISSOLVABLE THIN FILMS
5.4.2.1 REGULATORY COMPLIANCE
5.4.2.2 NICOTINE DOSAGE
5.4.2.3 WARNINGS AND PRECAUTIONS
5.4.2.4 EXPIRATION DATES
5.5 QUALITATIVE INFORMATION ON END USE OF NICOTINE ORAL DISSOLVABLE THIN FILMS
5.5.1 CHALLENGES IN FORMULATION, STABILITY, AND MANUFACTURING OF ORAL THIN FILM (OTF)
5.5.2 STRINGENT REGULATORY POLICIES FOR THE GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILM MARKET
5.6 QUALITATIVE INFORMATION ON END USE OF NICOTINE ORAL DISSOLVABLE THIN FILMS
5.6.1 SMOKERS & EX-SMOKERS
5.6.2 CONVENIENCE AND DISCREET USE
5.7 PRICING ANALYSIS, BY REGION 2023 (USD)
6 GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET, BY STRENGTH
6.1 OVERVIEW
6.2 1MG
6.3 2MG
6.4 OTHERS
7 GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 TONGUE
7.3 BUCCAL
8 GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 ADULTS
8.3 ADOLESCENTS
9 GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET, BY SALES CHANNEL
9.1 OVERVIEW
9.2 ONLINE
9.3 OFFLINE
10 GLOBAL NICOTINE ORAL DISSOLVABLE THIN FILMS MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 LATIN AMERICA
10.5.2 MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 AGREEMENT
11.6.2 EXPANSION
11.6.3 PRODUCT APPROVAL
11.6.4 PRODUCT RECOGNITION
12 COMPANY PROFILES
12.1 NICOCCINO HOLDING AB
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 ADDITIONAL INFORMATION
12.1.5 KEY DEVELOPMENTS
12.1.6 SWOT ANALYSIS
12.1.7 KEY STRATEGIES
12.2 NISSHA CO., LTD.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 ADDITIONAL INFORMATION
12.2.5 KEY DEVELOPMENTS
12.2.6 SWOT ANALYSIS
12.2.7 KEY STRATEGIES
12.3 ADHEXPHARMA
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCT OFFERED
12.3.4 ADDITIONAL INFORMATION
12.3.5 KEY DEVELOPMENTS
12.3.6 KEY STRATEGIES
12.4 ARX, LLC
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 ADDITIONAL INFORMATION
12.4.5 KEY DEVELOPMENTS
12.4.6 KEY STRATEGIES
12.5 ZIM LABORATORIES LIMITED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 ADDITIONAL INFORMATION
12.5.5 KEY DEVELOPMENTS
12.5.6 SWOT ANALYSIS
12.5.7 KEY STRATEGIES
12.6 LTS LOHMANN THERAPIE-SYSTEME AG
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 ADDITIONAL INFORMATION
12.6.5 KEY DEVELOPMENTS
12.6.6 SWOT ANALYSIS
12.6.7 KEY STRATEGIES
12.7 NAL PHARMA
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 ADDITIONAL INFORMATION
12.7.5 KEY DEVELOPMENTS
12.7.6 KEY STRATEGIES
12.8 INVENTZ
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 ADDITIONAL INFORMATION
12.8.5 KEY DEVELOPMENTS
12.8.6 SWOT ANALYSIS
12.8.7 KEY STRATEGIES
12.9 RENEJIX PHARMA SOLUTIONS
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 SERVICES OFFERED
12.9.4 ADDITIONAL INFORMATION
12.9.5 KEY DEVELOPMENTS
12.9.6 KEY STRATEGIES
12.10 DK LIVKON PVT. LTD
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 SERVICES OFFERED
12.10.4 ADDITIONAL INFORMATION
12.10.5 KEY DEVELOPMENTS
12.10.6 KEY STRATEGIES
13 DATA CITATIONS